

P A T E N T C L A I M S

1. Use of one or more synthetic CRH-R1 antagonists and /or
CRH-R2 agonists for the treatment of an inflammatory disease or condi-
5 tion associated to activation, deactivation, differentiation and apoptosis
of macrophages.

2. Use according to claim 1, wherein the one or more synthetic
CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.

3. Use according to claim 1 or 2, wherein the inflammatory dis-
10 ease or condition is chronic inflammatory bowel disease, idiopathic in-
flammatory disorder, inflammatory disorders of connective tissues, in-
flammatory demyelinating polyneuropathies, inflammatory myopathies,
inflammatory diseases of joints including bursitis, the fibromyalgia syn-
drome and inflammatory diseases of upper gastrointestinal tract.

4. Pharmaceutical composition comprising one or more syn-
15 thetic CRH-R1 antagonists and /or CRH-R2 agonists.

5. Pharmaceutical composition according to claim 4, wherein
the composition is formulated for local or systemic administration.

6. Pharmaceutical composition according to claim 4 or 5,
20 wherein the composition further comprises usual exhibients such as
diluent, fillers, binders, disintegrants, lubricants, conserving agents, fla-
vourings and colourings.

7. Pharmaceutical composition according to any of the claims 4
to 6, wherein the formulation is formulated for oral, parenteral or in-
25 tradermal administration.

8. Pharmaceutical composition according to claim 7, wherein
the composition is formulated as an injection liquid.

9. Pharmaceutical composition according to any of the claims
claim 4 to 8, wherein the one or more synthetic CRH-R1 antagonist
30 and/or CRH-R2 agonist comprises antalarmin.

10. Pharmaceutical composition according to claim 9, wherein the one of more synthetic CRH-R1 antagonist and/or CRH-R2 agonist is antalarmin.

11. Use of one or more synthetic CRH-R1 antagonists and /or
5 CRH-R2 agonists for the manufacture of a pharmaceutical composition for the treatment of an inflammatory disease or condition associated to activation, deactivation, differentiation and apoptosis of macrophages.

12. Use according to claim 11, wherein the inflammatory disease or condition is chronic inflammatory bowel disease, idiopathic inflammatory disorder, inflammatory disorders of connective tissues, inflammatory demyelinating polyneuropathies, inflammatory myopathies,
10 inflammatory diseases of joints including bursitis, the fibromyalgia syndrome and inflammatory diseases of upper gastrointestinal tract.

13. Kit intended for the treatment of an inflammatory disease or
15 condition comprising one or more CRH-R1 antagonists and /or CRH-R2 agonists comprised in one of more individual pharmaceutical compositions.

14. Kit according to claim 13, wherein the one or more CRH-R1 antagonists and/or CRH-R2 agonists comprises antalarmin.